Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leif E Sander

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Iscience|March 17, 2023
Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by OmicronJakob Kreye, S Momsen Reincke, Stefan Edelburg, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2025
Glycan microarray analysis of <i>Candida</i>-related antibodies in human and mice sera guides biomarker discovery and vaccine developmentEmelie E Reuber, Emer Hickey, Arnab Pradhan, et al.
Nature Nanotechnology|April 2, 2020
Phage capsid nanoparticles with defined ligand arrangement block influenza virus entryDaniel Lauster, Simon Klenk, Kai Ludwig, et al.
Infection|April 7, 2021
CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severityJan-Moritz Doehn, Christoph Tabeling, Robert Biesen, et al.
Nature Immunology|March 21, 2018
Recognition of microbial viability via TLR8 drives T<sub>FH</sub> cell differentiation and vaccine responsesMatteo Ugolini, Jenny Gerhard, Sanne Burkert, et al.
The Journal of Infectious Diseases|October 3, 2020
A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission SettingSarah M Hicks, Kai Pohl, Teresa Neeman, et al.
Infection|April 23, 2021
Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational studyCharlotte Thibeault, Barbara Mühlemann, Elisa T Helbig, et al.
NPJ Biofilms and Microbiomes|July 31, 2024
Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19Morgan Essex, Belén Millet Pascual-Leone, Ulrike Löber, et al.
Eclinicalmedicine|May 23, 2022
Highly multiplexed immune repertoire sequencing links multiple lymphocyte classes with severity of response to COVID-19Richard Dannebaum, Phillip Suwalski, Hosseinali Asgharian, et al.
Nature Communications|February 11, 2023
Distinct tissue niches direct lung immunopathology via CCL18 and CCL21 in severe COVID-19Ronja Mothes, Anna Pascual-Reguant, Ralf Koehler, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Iscience|March 17, 2023
Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by OmicronJakob Kreye, S Momsen Reincke, Stefan Edelburg, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 25, 2025
Glycan microarray analysis of <i>Candida</i>-related antibodies in human and mice sera guides biomarker discovery and vaccine developmentEmelie E Reuber, Emer Hickey, Arnab Pradhan, et al.
Nature Nanotechnology|April 2, 2020
Phage capsid nanoparticles with defined ligand arrangement block influenza virus entryDaniel Lauster, Simon Klenk, Kai Ludwig, et al.
Infection|April 7, 2021
CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severityJan-Moritz Doehn, Christoph Tabeling, Robert Biesen, et al.
Nature Immunology|March 21, 2018
Recognition of microbial viability via TLR8 drives T<sub>FH</sub> cell differentiation and vaccine responsesMatteo Ugolini, Jenny Gerhard, Sanne Burkert, et al.
The Journal of Infectious Diseases|October 3, 2020
A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission SettingSarah M Hicks, Kai Pohl, Teresa Neeman, et al.
Infection|April 23, 2021
Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational studyCharlotte Thibeault, Barbara Mühlemann, Elisa T Helbig, et al.
NPJ Biofilms and Microbiomes|July 31, 2024
Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19Morgan Essex, Belén Millet Pascual-Leone, Ulrike Löber, et al.
Eclinicalmedicine|May 23, 2022
Highly multiplexed immune repertoire sequencing links multiple lymphocyte classes with severity of response to COVID-19Richard Dannebaum, Phillip Suwalski, Hosseinali Asgharian, et al.
Nature Communications|February 11, 2023
Distinct tissue niches direct lung immunopathology via CCL18 and CCL21 in severe COVID-19Ronja Mothes, Anna Pascual-Reguant, Ralf Koehler, et al.
Pageof 8